Trial · NCT03296137
Results by group21
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 21
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants and Type of Reported Adverse Events | All Participants | Neutropenia | 25 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Trombocytopenia | 22 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Anemia | 22 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Infection | 6 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Hyponatremia | 2 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Hemorrhagic cystitis | 1 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Fatique | 6 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Vertigo | 1 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Performance status drop | 4 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Thrombosis | 1 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Fever | 16 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Dyspnea | 6 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Hepatitis | 2 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Colitis | 2 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Transaminase elevation | 2 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Vomiting | 2 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Hallucination | 1 | Participants | |
| Number of Participants and Type of Reported Adverse Events | All Participants | Elevated creatinine | 1 | Participants | |
| Time to Disease Progression | Treated Participants | 89 | Full Range 12 to 211 | Days | |
| Overall Survival | Treated Participants | 227 | Full Range 50 to 870 | Days |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296137/results